Disease Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
KRAS G12X Oxaliplatin colorectal adenocarcinoma sensitive detail...
Unknown unknown VX-970 + Irinotecan colorectal adenocarcinoma not applicable detail...
BRCA2 del Cisplatin colorectal adenocarcinoma sensitive detail...
BRCA2 del PR-104 colorectal adenocarcinoma sensitive detail...
BRCA2 del Evofosfamide colorectal adenocarcinoma sensitive detail...
BRCA2 del Chlorambucil colorectal adenocarcinoma sensitive detail...
BRAF V600E DEL-22379 colorectal adenocarcinoma sensitive detail...
FGFR2 amp RO4987655 colorectal adenocarcinoma decreased response detail...
KRAS G13D RO4987655 colorectal adenocarcinoma sensitive detail...
FGFR2 amp RO5126766 colorectal adenocarcinoma predicted - sensitive detail...
KRAS G13D RO5126766 colorectal adenocarcinoma sensitive detail...
FGFR2 amp Selumetinib colorectal adenocarcinoma no benefit detail...
KRAS G13D Selumetinib colorectal adenocarcinoma predicted - sensitive detail...
Unknown unknown CRLX101 + Fluorouracil + Radiotherapy colorectal adenocarcinoma not applicable detail...
ERBB2 amp trastuzumab emtansine colorectal adenocarcinoma sensitive detail...
BRCA2 wild-type AZD6738 + Radiotherapy colorectal adenocarcinoma sensitive detail...
BRCA2 loss AZD6738 + Radiotherapy colorectal adenocarcinoma sensitive detail...
KRAS wild-type Cetuximab + Dasatinib + FOLFOX colorectal adenocarcinoma no benefit detail...
KRAS mutant Dasatinib + FOLFOX colorectal adenocarcinoma no benefit detail...
Unknown unknown CS-11 colorectal adenocarcinoma not applicable detail...
FGFR2 amp FGFR2-COL14A1 PRN1371 colorectal adenocarcinoma sensitive detail...
CTNNB1 S45F NTRC 0066-0 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S33Y NTRC 0066-0 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S45F Mps-BAY2b colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S33Y Mps-BAY2b colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S33Y NMS-P715 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S45F NMS-P715 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S45del BAY1161909 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S33Y BAY1161909 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S33Y BAY1217389 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S45F BAY1217389 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S45F Mps1-IN-1 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S33Y Mps1-IN-1 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S33Y MPI-0479605 colorectal adenocarcinoma predicted - sensitive detail...
CTNNB1 S45F MPI-0479605 colorectal adenocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00408772 Phase II Capecitabine + Oxaliplatin + Bevacizumab Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Cannot Be Removed By Surgery Withdrawn
NCT00842257 Phase II Panitumumab Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer Completed
NCT01061515 Phase I Capecitabine Bevacizumab Oxaliplatin Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer Recruiting
NCT01079780 Phase II Irinotecan + Cetuximab + Ramucirumab Cetuximab + Irinotecan Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy Active, not recruiting
NCT01420874 Phase I EGFRBi-armed autologous activated T cells Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Anti-CD3 x Anti-Erbitux Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer) Active, not recruiting
NCT01442935 Phase II Bevacizumab + FOLFOX Cetuximab + FOLFIRI Bevacizumab + FOLFIRI Cetuximab + FOLFOX Bevacizumab + FOLFIRINOX Cetuximab + FOLFIRINOX Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases Active, not recruiting
NCT01471353 Phase II Sorafenib + Capecitabine Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer Completed
NCT01571284 Phase III Aflibercept + FOLFIRI Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen Completed
NCT01622543 Phase II Bevacizumab + FOLFOX Reolysin Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer Unknown status
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Recruiting
NCT01652196 Phase II Aflibercept + mFOLFOX-6 Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer Active, not recruiting
NCT01652482 Phase II Cetuximab MEHD7945A FOLFIRI A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer Completed
NCT01802320 Phase II MK2206 Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Active, not recruiting
NCT01814501 Phase II FOLFIRI Panitumumab Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab Recruiting
NCT01949194 Phase II Regorafenib Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers Active, not recruiting
NCT02023333 Phase II Regorafenib Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma Active, not recruiting
NCT02024607 Phase Ib/II Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin FOLFIRI A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Active, not recruiting
NCT02116894 Phase I PF-03446962 + Regorafenib Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer Completed
NCT02149108 Phase III Nintedanib Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer Completed
NCT02235324 Phase II Aflibercept + Leucovorin + Fluorouracil Aflibercept Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Withdrawn
NCT02248805 Phase I MGD007 Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma Completed
NCT02292758 Phase II Bevacizumab + Cetuximab + Irinotecan Cetuximab + Irinotecan Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer Active, not recruiting
NCT02368886 Phase II Clobetasol + Regorafenib Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer Active, not recruiting
NCT02375672 Phase II Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer Active, not recruiting
NCT02413853 Phase II Bevacizumab Pri-724 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer Withdrawn
NCT02466009 Phase II Regorafenib Regorafenib in Metastatic Colorectal Cancer Recruiting
NCT02509507 Phase I Pembrolizumab + talimogene laherparepvec talimogene laherparepvec Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab Recruiting
NCT02574663 Phase I Nab-paclitaxel + Gemcitabine Bevacizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Umbralisib TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors Active, not recruiting
NCT02602327 Phase I trifluridine/tipiracil hydrochloride Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases Recruiting
NCT02638909 Phase II Ceritinib Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies Terminated
NCT02650635 Phase I Cyclophosphamide + Pegfilgrastim + VTX-2337 TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors Terminated
NCT02651415 Phase II Perindopril + Regorafenib Phase II Study of Perindopril and Regorafenib in mCRC Active, not recruiting
NCT02675946 Phase I CGX1321 Study of CGX1321 in Subjects With Advanced Solid Tumors Recruiting
NCT02780700 Phase II Capecitabine + Nintedanib Nintedanib Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2] Terminated
NCT02835833 Phase I Bevacizumab + Nintedanib Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors Completed
NCT02860546 Phase II Nivolumab + trifluridine/tipiracil hydrochloride A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC Completed
NCT02876224 Phase I Cobimetinib + Bevacizumab + Atezolizumab Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Active, not recruiting
NCT02908451 Phase I AbGn-107 A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer Recruiting
NCT03007407 Phase II Tremelimumab Durvalumab Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy Recruiting
NCT03069950 Phase II Floxiuridine + Panitumumab + Dexamethasone + FOLFIRI Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver Recruiting
NCT03081494 Phase I PDR001 + Regorafenib Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer Recruiting
NCT03087071 Phase II Panitumumab Trametinib Panitumumab in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer Recruiting
NCT03095781 Phase I Pembrolizumab + XL888 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Recruiting
NCT03104439 Phase II Nivolumab + Ipilimumab Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer Recruiting
NCT03192345 Phase I SAR439459 + REGN2810 SAR439459 A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors Recruiting
NCT03258398 Phase II Avelumab + eFT508 eFT508 A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer Active, not recruiting
NCT03277209 Phase I Plerixafor To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas Active, not recruiting
NCT03300609 Phase III Capecitabine Panitumumab + FOLFOX Panitumumab + Fluorouracil + Leucovorin 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab Recruiting
NCT03332498 Phase Ib/II Pembrolizumab + Ibrutinib Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers Recruiting
NCT03337087 Phase Ib/II Fluorouracil + Irinotecan + Leucovorin + Rucaparib Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib Phosphate in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer Recruiting
NCT03366155 Phase II Floxuridine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Panitumumab Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver Recruiting
NCT03373188 Phase I Nivolumab + VX15/2503 Ipilimumab + VX15/2503 VX15/2503 VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer Recruiting
NCT03376659 Phase Ib/II Capecitabine + CV301 + Durvalumab Bevacizumab + Capecitibine + CV301 + Durvalumab Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma Recruiting
NCT03384940 Phase II DS-8201a DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer Recruiting
NCT03396926 Phase II Bevacizumab + Capecitabine + Pembrolizumab Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Recruiting
NCT03436563 Phase Ib/II M7824 M7824 in Consensus Molecular Subtype 4, Treatment-Refractory Metastatic Colorectal Cancer Recruiting
NCT03442569 Phase II Ipilimumab + Nivolumab + Panitumumab PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC Recruiting
NCT03475004 Phase II Bevacizumab + Binimetinib + Pembrolizumab Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer Recruiting
NCT03539822 Phase I Cabozantinib + Durvalumab Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA) Recruiting
NCT03542877 Phase II Cabozantinib Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer Recruiting
NCT03576963 Phase Ib/II Guadecitabine + Nivolumab Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer Not yet recruiting
NCT03642067 Phase II Nivolumab + Relatlimab Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer Recruiting
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting
NCT03712943 Phase I Nivolumab + Regorafenib Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer Recruiting
NCT03715933 Phase I INBRX-109 Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Recruiting
NCT03800602 Phase II Metformin + Nivolumab Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer Recruiting